<p>阿什顿·托马斯证券公司在第三季度购买了诺华制药（NYSE:NVS - 免费报告）的新头寸，根据其最近向证券交易委员会的披露。这家机构投资者购买了 34,439 股该公司的股票，价值约为 4,416,000 美元。</p>
<ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
<p>其他几家机构投资者也对该公司的头寸进行了调整。Keybank National Association OH 在第二季度将其在诺华的股份提高了 13.2%。Keybank National Association OH 目前拥有 49,377 股该公司的股票，价值为 5,975,000 美元，在上个季度又购买了 5,742 股。Geneos Wealth Management Inc.在第三季度将其在诺华的持股提高了 27.7%。Geneos Wealth Management Inc.目前拥有 64,760 股该公司的股票，价值为 8,305,000 美元，在上个季度又购买了 14,032 股。HM Payson &amp; Co.在第三季度将其在诺华的持股提高了 306.6%。HM Payson &amp; Co.目前拥有 13,262 股该公司的股票，价值为 1,701,000 美元，在上个季度又购买了 10,000 股。Sonora Investment Management Group LLC 在第二季度获得了诺华的新股份，价值为 266,000 美元。最后，Cypress Capital Group 在第二季度将其在诺华的持股提高了 84.1%。Cypress Capital Group 目前拥有 5,776 股该公司的股票，价值为 699,000 美元。当前 13.12% 的股票由机构投资者和对冲基金持有。</p>
<h2>诺华股价上涨 0.0%</h2>
<p>诺华股票周三开盘价为 141.85 美元。诺华制药的 1 年最低价为 97.39 美元，1 年最高价为 143.49 美元。该公司的 50 日简单移动平均线为 133.67 美元，200 日简单移动平均线为 127.41 美元。该公司的市值为 2996.5 亿美元，市盈率为 19.38，PEG 比率为 1.95，贝塔值为 0.51。该公司的流动比率为 0.88，速动比率为 0.68，债务与股本比率为 0.50。</p>
<ul>
<li>三只大型制药股在美国投资超过 1000 亿美元。</li>
</ul>
<p>诺华（NYSE:NVS - 获取免费报告）在 10 月 28 日星期二发布了最新的财报。该公司报告本季度每股收益为 2.25 美元，低于市场共识预期的 2.26 美元（差额为 0.01 美元）。该公司本季度的收入为 143.6 亿美元，而分析师预期为 137 亿美元。诺华的净利润率为 26.49%，股本回报率为 41.21%。与去年同期相比，诺华本季度的收入增长了 8.5%。在去年同期，该公司每股收益为 2.06 美元。整体来看，卖方分析师预计诺华制药在当前年度将发布 8.45 美元的每股收益。</p>
<h2>分析师设定新的目标价</h2>
<p>几家研究公司对 NVS 发表了看法。汇丰银行在 12 月 10 日的报告中重申了 “减持” 评级，并将诺华的目标价设定为 112.00 美元。摩根士丹利在 12 月 3 日的研究报告中重新发布了诺华的 “增持” 评级。华尔街 Zen 在 1 月 3 日的研究报告中将诺华的评级从 “买入” 下调至 “持有”。Weiss Ratings 在 12 月 29 日的报告中重申了诺华的 “买入（b）” 评级。最后，Cowen 在 11 月 10 日的研究报告中重申了诺华的 “持有” 评级。一位投资分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，七位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，诺华目前的平均评级为 “持有”，共识目标价为 119.75 美元。</p>
<ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
<p><strong>查看我们关于 NVS 的最新研究报告</strong></p>
<h2>诺华公司简介</h2>
<p>（免费报告）</p>
<p>诺华是一家总部位于巴塞尔的瑞士跨国制药公司，专注于研究、开发、生产和商业化处方药及相关医疗产品。诺华通过 1996 年 Ciba-Geigy 与 Sandoz 的合并而成立，业务遍及全球，致力于将治疗药物从发现阶段通过临床开发推向全球市场。</p>
<p>该公司的活动集中在多个治疗领域的创新药物上，包括肿瘤学、免疫学、心血管和代谢疾病、神经科学和眼科，同时具备生物制剂、细胞和基因疗法等先进疗法的能力。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过诺华</li>
<li>股票即将迎来 “不祥之日”……</li>
<li>将这些代码输入您的普通经纪账户</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
<li>特朗普刚刚签署了它</li>
<li>崩盘前一个月</li>
</ul>
<p><strong>想看看其他对冲基金持有什么 NVS 吗？</strong> 访问 HoldingsChannel.com，获取诺华制药（NYSE:NVS - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在诺华吗？</h2>
<p>在考虑诺华之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而诺华并不在名单上。</p>
<p>虽然诺华目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看五只股票</p>

诺华制药

<p>Ashton Thomas Securities LLC 在第三季度收购了 34,439 股诺华制药（Novartis AG，NYSE:NVS），价值约 440 万美元。其他机构投资者也增加了他们的持股，Keybank National Association 将其持股提高了 13.2%。诺华在第三季度报告的每股收益为 2.25 美元，略低于预期，但收入增长至 143.6 亿美元。分析师对诺华的评级不一，平均评级为 “持有”，共识目标价为 119.75 美元。该公司专注于各类治疗领域的创新药物</p>

<p>Ashton Thomas Securities LLC bought a new position in Novartis AG (NYSE:NVS - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 34,439 shares of the company's stock, valued at approximately $4,416,000.</p>
<div class="lb-trans"><p>阿什顿·托马斯证券公司在第三季度购买了诺华制药（NYSE:NVS - 免费报告）的新头寸，根据其最近向证券交易委员会的披露。这家机构投资者购买了 34,439 股该公司的股票，价值约为 4,416,000 美元。</p>
</div><ul>
<li>Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver</li>
</ul>
<div class="lb-trans"><ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
</div><p>Several other institutional investors have also made changes to their positions in the company. Keybank National Association OH lifted its stake in Novartis by 13.2% in the second quarter. Keybank National Association OH now owns 49,377 shares of the company's stock valued at $5,975,000 after acquiring an additional 5,742 shares during the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Novartis by 27.7% during the 3rd quarter. Geneos Wealth Management Inc. now owns 64,760 shares of the company's stock valued at $8,305,000 after purchasing an additional 14,032 shares in the last quarter. HM Payson &amp; Co. raised its holdings in shares of Novartis by 306.6% during the 3rd quarter. HM Payson &amp; Co. now owns 13,262 shares of the company's stock valued at $1,701,000 after purchasing an additional 10,000 shares in the last quarter. Sonora Investment Management Group LLC acquired a new stake in shares of Novartis in the 2nd quarter valued at $266,000. Finally, Cypress Capital Group boosted its holdings in Novartis by 84.1% in the second quarter. Cypress Capital Group now owns 5,776 shares of the company's stock worth $699,000 after purchasing an additional 2,638 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者也对该公司的头寸进行了调整。Keybank National Association OH 在第二季度将其在诺华的股份提高了 13.2%。Keybank National Association OH 目前拥有 49,377 股该公司的股票，价值为 5,975,000 美元，在上个季度又购买了 5,742 股。Geneos Wealth Management Inc.在第三季度将其在诺华的持股提高了 27.7%。Geneos Wealth Management Inc.目前拥有 64,760 股该公司的股票，价值为 8,305,000 美元，在上个季度又购买了 14,032 股。HM Payson &amp; Co.在第三季度将其在诺华的持股提高了 306.6%。HM Payson &amp; Co.目前拥有 13,262 股该公司的股票，价值为 1,701,000 美元，在上个季度又购买了 10,000 股。Sonora Investment Management Group LLC 在第二季度获得了诺华的新股份，价值为 266,000 美元。最后，Cypress Capital Group 在第二季度将其在诺华的持股提高了 84.1%。Cypress Capital Group 目前拥有 5,776 股该公司的股票，价值为 699,000 美元。当前 13.12% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Novartis Trading Up 0.0%</h2>
<div class="lb-trans"><h2>诺华股价上涨 0.0%</h2>
</div><p>Shares of Novartis stock opened at $141.85 on Wednesday. Novartis AG has a 1 year low of $97.39 and a 1 year high of $143.49. The company's fifty day simple moving average is $133.67 and its 200-day simple moving average is $127.41. The company has a market cap of $299.65 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 1.95 and a beta of 0.51. The company has a current ratio of 0.88, a quick ratio of 0.68 and a debt-to-equity ratio of 0.50.</p>
<div class="lb-trans"><p>诺华股票周三开盘价为 141.85 美元。诺华制药的 1 年最低价为 97.39 美元，1 年最高价为 143.49 美元。该公司的 50 日简单移动平均线为 133.67 美元，200 日简单移动平均线为 127.41 美元。该公司的市值为 2996.5 亿美元，市盈率为 19.38，PEG 比率为 1.95，贝塔值为 0.51。该公司的流动比率为 0.88，速动比率为 0.68，债务与股本比率为 0.50。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>三只大型制药股在美国投资超过 1000 亿美元。</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last released its earnings results on Tuesday, October 28th. The company reported $2.25 EPS for the quarter, missing the consensus estimate of $2.26 by ($0.01). The company had revenue of $14.36 billion for the quarter, compared to analyst estimates of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. Novartis's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.06 earnings per share. As a group, sell-side analysts expect that Novartis AG will post 8.45 EPS for the current year.</p>
<div class="lb-trans"><p>诺华（NYSE:NVS - 获取免费报告）在 10 月 28 日星期二发布了最新的财报。该公司报告本季度每股收益为 2.25 美元，低于市场共识预期的 2.26 美元（差额为 0.01 美元）。该公司本季度的收入为 143.6 亿美元，而分析师预期为 137 亿美元。诺华的净利润率为 26.49%，股本回报率为 41.21%。与去年同期相比，诺华本季度的收入增长了 8.5%。在去年同期，该公司每股收益为 2.06 美元。整体来看，卖方分析师预计诺华制药在当前年度将发布 8.45 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的目标价</h2>
</div><p>Several research firms have weighed in on NVS. HSBC restated a &#34;reduce&#34; rating and set a $112.00 target price on shares of Novartis in a report on Wednesday, December 10th. Morgan Stanley reissued an &#34;overweight&#34; rating on shares of Novartis in a research note on Wednesday, December 3rd. Wall Street Zen cut Novartis from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, January 3rd. Weiss Ratings reiterated a &#34;buy (b)&#34; rating on shares of Novartis in a report on Monday, December 29th. Finally, Cowen restated a &#34;hold&#34; rating on shares of Novartis in a research note on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Novartis presently has an average rating of &#34;Hold&#34; and a consensus target price of $119.75.</p>
<div class="lb-trans"><p>几家研究公司对 NVS 发表了看法。汇丰银行在 12 月 10 日的报告中重申了 “减持” 评级，并将诺华的目标价设定为 112.00 美元。摩根士丹利在 12 月 3 日的研究报告中重新发布了诺华的 “增持” 评级。华尔街 Zen 在 1 月 3 日的研究报告中将诺华的评级从 “买入” 下调至 “持有”。Weiss Ratings 在 12 月 29 日的报告中重申了诺华的 “买入（b）” 评级。最后，Cowen 在 11 月 10 日的研究报告中重申了诺华的 “持有” 评级。一位投资分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，七位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，诺华目前的平均评级为 “持有”，共识目标价为 119.75 美元。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
</div><p><strong>View Our Latest Research Report on NVS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 NVS 的最新研究报告</strong></p>
</div><h2>Novartis Company Profile</h2>
<div class="lb-trans"><h2>诺华公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.</p>
<div class="lb-trans"><p>诺华是一家总部位于巴塞尔的瑞士跨国制药公司，专注于研究、开发、生产和商业化处方药及相关医疗产品。诺华通过 1996 年 Ciba-Geigy 与 Sandoz 的合并而成立，业务遍及全球，致力于将治疗药物从发现阶段通过临床开发推向全球市场。</p>
</div><p>The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.</p>
<div class="lb-trans"><p>该公司的活动集中在多个治疗领域的创新药物上，包括肿瘤学、免疫学、心血管和代谢疾病、神经科学和眼科，同时具备生物制剂、细胞和基因疗法等先进疗法的能力。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>“Ominous day” coming to stocks…</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>Trump just signed it</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过诺华</li>
<li>股票即将迎来 “不祥之日”……</li>
<li>将这些代码输入您的普通经纪账户</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
<li>特朗普刚刚签署了它</li>
<li>崩盘前一个月</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding NVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有什么 NVS 吗？</strong> 访问 HoldingsChannel.com，获取诺华制药（NYSE:NVS - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺华之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而诺华并不在名单上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺华目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看五只股票</p>
</div>

Ashton Thomas Securities LLC 收购了诺华制药（NOVARTIS AG）$NVS 的新股份